Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: WTAP

Gene summary for WTAP

Gene summary.

Gene information	Species	Human
	Gene symbol	WTAP
	Gene ID	9589
	Gene name	WT1 associated protein
	Gene Alias	Mum2
	Cytomap	6q25.3
	Gene Type	protein-coding
	GO ID	GO:0000375
	UniProtAcc	Q15007

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
9589	WTAP	GSM4909285	Human	Breast	IDC	4.20e-09	-4.47e-01	0.21
9589	WTAP	GSM4909286	Human	Breast	IDC	2.78e-08	-2.13e-01	0.1081
9589	WTAP	GSM4909288	Human	Breast	IDC	1.46e-03	-4.52e-01	0.0988
9589	WTAP	GSM4909291	Human	Breast	IDC	1.46e-14	-6.05e-01	0.1753
9589	WTAP	GSM4909292	Human	Breast	IDC	2.24e-05	-7.57e-01	0.1236
9589	WTAP	GSM4909293	Human	Breast	IDC	7.75e-04	-2.96e-01	0.1581
9589	WTAP	GSM4909294	Human	Breast	IDC	3.32e-12	-5.67e-01	0.2022
9589	WTAP	GSM4909296	Human	Breast	IDC	3.72e-36	-7.32e-01	0.1524
9589	WTAP	GSM4909297	Human	Breast	IDC	9.34e-19	-3.45e-01	0.1517
9589	WTAP	GSM4909298	Human	Breast	IDC	4.93e-07	-3.86e-01	0.1551
9589	WTAP	GSM4909299	Human	Breast	IDC	3.74e-04	-3.22e-01	0.035
9589	WTAP	GSM4909301	Human	Breast	IDC	5.13e-08	-4.64e-01	0.1577
9589	WTAP	GSM4909302	Human	Breast	IDC	5.26e-25	-5.93e-01	0.1545
9589	WTAP	GSM4909304	Human	Breast	IDC	2.32e-06	-4.15e-01	0.1636
9589	WTAP	GSM4909305	Human	Breast	IDC	4.28e-02	-2.33e-01	0.0436
9589	WTAP	GSM4909306	Human	Breast	IDC	4.09e-10	-4.35e-01	0.1564
9589	WTAP	GSM4909307	Human	Breast	IDC	2.37e-17	-5.72e-01	0.1569
9589	WTAP	GSM4909308	Human	Breast	IDC	8.16e-11	-4.18e-01	0.158
9589	WTAP	GSM4909309	Human	Breast	IDC	1.21e-13	-4.67e-01	0.0483
9589	WTAP	GSM4909311	Human	Breast	IDC	1.47e-40	-7.04e-01	0.1534

Page: 1 2 3 4 5 6 7 8 9 10 11

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Cervix	N_HPV
Endometrium	AEH
Endometrium	EEC
Prostate	BPH
Prostate	Tumor

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00083809	Breast	Precancer	RNA splicing	65/1080	434/18723	1.27e-12	2.53e-10	65
GO:00434849	Breast	Precancer	regulation of RNA splicing	34/1080	148/18723	2.66e-12	4.75e-10	34
GO:00003759	Breast	Precancer	RNA splicing, via transesterification reactions	52/1080	324/18723	1.74e-11	2.22e-09	52
GO:00003779	Breast	Precancer	RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	51/1080	320/18723	3.55e-11	4.04e-09	51
GO:00003989	Breast	Precancer	mRNA splicing, via spliceosome	51/1080	320/18723	3.55e-11	4.04e-09	51
GO:00480249	Breast	Precancer	regulation of mRNA splicing, via spliceosome	22/1080	101/18723	5.29e-08	3.18e-06	22
GO:19033118	Breast	Precancer	regulation of mRNA metabolic process	38/1080	288/18723	1.63e-06	5.97e-05	38
GO:00506848	Breast	Precancer	regulation of mRNA processing	23/1080	137/18723	3.49e-06	1.13e-04	23
GO:00003808	Breast	Precancer	alternative mRNA splicing, via spliceosome	15/1080	77/18723	2.86e-05	6.37e-04	15
GO:00003818	Breast	Precancer	regulation of alternative mRNA splicing, via spliceosome	13/1080	60/18723	2.98e-05	6.58e-04	13
GO:000838014	Breast	IDC	RNA splicing	73/1434	434/18723	1.27e-10	1.57e-08	73
GO:004348414	Breast	IDC	regulation of RNA splicing	36/1434	148/18723	3.32e-10	3.77e-08	36
GO:000037514	Breast	IDC	RNA splicing, via transesterification reactions	58/1434	324/18723	9.44e-10	9.58e-08	58
GO:000037714	Breast	IDC	RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	57/1434	320/18723	1.60e-09	1.49e-07	57
GO:000039814	Breast	IDC	mRNA splicing, via spliceosome	57/1434	320/18723	1.60e-09	1.49e-07	57
GO:004802414	Breast	IDC	regulation of mRNA splicing, via spliceosome	23/1434	101/18723	1.74e-06	7.28e-05	23
GO:005068413	Breast	IDC	regulation of mRNA processing	24/1434	137/18723	1.09e-04	2.04e-03	24
GO:190331113	Breast	IDC	regulation of mRNA metabolic process	40/1434	288/18723	1.79e-04	3.01e-03	40
GO:000038113	Breast	IDC	regulation of alternative mRNA splicing, via spliceosome	13/1434	60/18723	5.09e-04	6.65e-03	13
GO:000038013	Breast	IDC	alternative mRNA splicing, via spliceosome	15/1434	77/18723	6.51e-04	8.04e-03	15

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

WTAP

SNV

Missense_Mutation

c.152N>C

p.Asp51Ala

p.D51A

Q15007

protein_coding

tolerated(0.07)

possibly_damaging(0.78)

TCGA-A2-A04P-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

taxol

WTAP

SNV

Missense_Mutation

c.236G>A

p.Arg79Gln

p.R79Q

Q15007

protein_coding

deleterious(0.04)

benign(0.38)

TCGA-A8-A07R-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Ancillary

zoledronic

WTAP

SNV

Missense_Mutation

rs375840138

c.1001N>T

p.Ala334Val

p.A334V

Q15007

protein_coding

tolerated_low_confidence(0.33)

benign(0)

TCGA-D8-A1J8-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

nolvadex

WTAP

SNV

Missense_Mutation

c.485N>C

p.Arg162Pro

p.R162P

Q15007

protein_coding

deleterious(0)

possibly_damaging(0.899)

TCGA-D8-A1XB-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

WTAP

SNV

Missense_Mutation

rs369657864

c.932A>G

p.Asn311Ser

p.N311S

Q15007

protein_coding

tolerated_low_confidence(0.51)

benign(0.025)

TCGA-XX-A89A-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

WTAP

insertion

Nonsense_Mutation

novel

c.573_574insCCAACTGCACTCCAGCCTGGGCTACAGAGTGAGACTCCATCCTAA

p.Lys191_Lys192insProThrAlaLeuGlnProGlyLeuGlnSerGluThrProSerTer

p.K191_K192insPTALQPGLQSETPS*

Q15007

protein_coding

TCGA-A2-A04P-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

taxol

WTAP

insertion

Frame_Shift_Ins

novel

c.929_930insCTTGCTTTGTGGCAGGCAC

p.Asn311LeufsTer7

p.N311Lfs*7

Q15007

protein_coding

TCGA-A8-A06X-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

WTAP

insertion

Frame_Shift_Ins

novel

c.931_932insAAGAAACATTTTTCAATGTT

p.Asn311LysfsTer26

p.N311Kfs*26

Q15007

protein_coding

TCGA-A8-A06X-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

WTAP

SNV

Missense_Mutation

novel

c.1082A>G

p.Asp361Gly

p.D361G

Q15007

protein_coding

deleterious_low_confidence(0.01)

benign(0.084)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

WTAP

SNV

Missense_Mutation

c.448N>C

p.Asp150His

p.D150H

Q15007

protein_coding

deleterious(0.03)

probably_damaging(0.98)

TCGA-DG-A2KK-01

Cervix

cervical & endocervical cancer

Female

<65

III/IV

Chemotherapy

cisplatin

Page: 1 2 3 4 5

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1